CME Sam Continuing Medical Education and Self Assessment Modules

Continuing Medical Education and Self Assessment Modules: Meetings, Webinars, and Self Study Courses

New Treatments in Chronic Liver Disease
Saturday, March 21, 2015 - Sunday, March 22, 2015

CME Provider:
Scripps Conference Services & CME ›
11025 North Torrey Pines Road, Ste. 200
Mail drop: SCRC 200
La Jolla, California (CA) 92037
United States

Phone: (858) 652-5400
Fax: (858) 652-5565

Visit the CME Provider Webpage ›

Conference Center:
Estancia La Jolla Hotel & Spa ›
9700 N. Torrey Pines Road
La Jolla, California (CA) 92037
United States

Phone: (855) 318-7602

Visit the Conference Center Webpage ›

Description:
"This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, cholangiocarcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.

There was a fundamental change in the treatment of chronic hepatitis C in 2014 with the addition of 2 new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on triple therapies that were approved in late 2013. The second will be on future therapies using two or more DAA’s without interferons.

We anticipate that there will be a number of new demands placed on treatment providers, including screening, access to treatment, costs of therapy and the continuation of complex algorithms for interferon-based regimens. Looking beyond 2014, we see numerous combinations of DAA’s in development including protease inhibitors, nucleoside polymerase inhibitors, non-nucleoside polymerase inhibitors and N55A inhibitors. All of these agents are in phase 3 development and a number have completed studies and are awaiting FDA review. In hepatitis B, the treatments have not changed but there is more mature data available on renal resistance, long-term HBsAg loss and clinical outcomes. The addition of hepatitis E as an important disease and a treatable form of viral hepatitis has been included in this year’s program. New therapies for NAFLD and NASH are in development and will be explored. The explosive growth of NASH in the US has created a significant need for effective drug therapy. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. New oral therapy is moving this field forward. There will be an update on management of hepatic encephalopathy, hyponatremia and the management of pulmonary complications in the transplant candidate."

Visit the CME Course Webpage ›

Instructors:
Paul Pockros, MD, FACG

CME Credit:
Physicians:  13.5 Hours
Physician Assistants:  Credit Available
Nurses:  Credit Available

Self Assessment Module (SAM): No

Specialty Audience:
Family Medicine    Internal Medicine    Surgery

CME Sam Course #10259

Map of Estancia La Jolla Hotel & Spa, 9700 N. Torrey Pines Road, La Jolla, California (CA), United States

Show Nearby: Rank By:

Healthcare Professionals CME Providers Advertise About Us

Terms of Use Privacy Policy

Copyright © 2013 Maxwell Publishing Company. All rights reserved.
The CME Sam logo and 'What's News In CME' are registered U.S. trademarks.

Follow Us